APA (7th ed.) Citation

Shin, S., Kim, H., Yoon, H., Park, W., Adams, D. R., Pyne, N. J., . . . Park, J. (2020). A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes. International Journal of Molecular Sciences, 21(21), 8371. https://doi.org/10.3390/ijms21218371

Chicago Style (17th ed.) Citation

Shin, Sun-Hye, Hee-Yeon Kim, Hee-Soo Yoon, Woo-Jae Park, David R. Adams, Nigel J. Pyne, Susan Pyne, and Joo-Won Park. "A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes." International Journal of Molecular Sciences 21, no. 21 (2020): 8371. https://doi.org/10.3390/ijms21218371.

MLA (9th ed.) Citation

Shin, Sun-Hye, et al. "A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes." International Journal of Molecular Sciences, vol. 21, no. 21, 2020, p. 8371, https://doi.org/10.3390/ijms21218371.